Zymeworks: From Bespoke Therapeutics to a Royalty-Backed Biopharma Platform
Zymeworks is shifting its identity from a development-stage biotech to a hybrid commercial/royalty-driven platform. With licensed assets in the mix, a $929M acquisition of Theravance (bringing YUPELRI® with $266.6M in 2025 U.S. sales), fresh commercial upside and a deeper R&D bench, the company has optionality that could justify a higher multiple. …